Organization | AGUNCO Obstetrics and Gynecology Centre

AGUNCO Obstetrics and Gynecology Centre Report issue

Academic/Hospital Phase 4

Founded: Rome Italy (2000)

Organization Overview

First Clinical Trial

2010

NCT01246310

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

AGUNCO Obstetrics and Gynecology Centre

Active Ingredients

Drugs in Phase 4 Trials (11)

alpha-lipoic acid (1 trial)

cyanocobalamin (berocca) (1 trial)

drospirenone (Yasmin) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

folic acid (6 trials)

follitropin alfa (Gonal-F) (1 trial)

hyaluronic acid (1 trial)

magnesium oxide (1 trial)

manganese (1 trial)

melatonin (3 trials)

myoinositol (11 trials)

Drugs in Other Trials (2)

alpha-lactalbumin (1 trial)

d-chiro-inositol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Asthenozoospermia (Phase 3)

Atrophic Vaginitis (Phase 4)

Atrophy (Phase 4)

Diabetes, Gestational (Phase 4)

Infertility (Phase 4)

Insulin Resistance (Phase 4)

Mental Disorders (Phase 4)

Oligospermia (Phase 3)

Polycystic Ovary Syndrome (Phase 4)

Problem Behavior (Phase 4)

Syndrome (Phase 4)

Vaginitis (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 15
# of Trial APIs: 13